Heartflow, Inc. (NASDAQ:HTFL) Short Interest Update

Heartflow, Inc. (NASDAQ:HTFL) was the target of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 5,453,610 shares, an increase of 19.6% from the February 12th total of 4,560,254 shares. Based on an average daily trading volume, of 1,242,370 shares, the days-to-cover ratio is currently 4.4 days. Approximately 6.4% of the shares of the stock are short sold. Approximately 6.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,242,370 shares, the days-to-cover ratio is currently 4.4 days.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Canaccord Genuity Group reissued a “buy” rating and set a $40.00 price target on shares of Heartflow in a research note on Monday, March 9th. Wells Fargo & Company initiated coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Heartflow Stock Performance

Shares of HTFL traded up $2.25 during mid-day trading on Wednesday, reaching $24.77. 703,662 shares of the company were exchanged, compared to its average volume of 1,393,241. The business has a 50 day simple moving average of $27.30 and a two-hundred day simple moving average of $30.52. Heartflow has a 52 week low of $20.13 and a 52 week high of $41.22. The stock has a market capitalization of $2.11 billion and a PE ratio of -13.70.

Insiders Place Their Bets

In other news, insider Campbell Rogers sold 65,153 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $24.49, for a total value of $1,595,596.97. Following the sale, the insider directly owned 76,034 shares in the company, valued at approximately $1,862,072.66. This trade represents a 46.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Julie A. Cullivan sold 9,122 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $25.00, for a total transaction of $228,050.00. Following the completion of the sale, the director owned 27,291 shares in the company, valued at $682,275. This represents a 25.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 2,117,674 shares of company stock valued at $59,052,646.

Institutional Investors Weigh In On Heartflow

Several large investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow during the 4th quarter worth about $27,000. TFC Financial Management Inc. acquired a new stake in shares of Heartflow during the 3rd quarter worth approximately $40,000. Russell Investments Group Ltd. acquired a new stake in Heartflow in the fourth quarter worth $45,000. Legal & General Group Plc bought a new stake in Heartflow in the 3rd quarter valued at about $59,000. Finally, Strs Ohio bought a new stake in shares of Heartflow during the fourth quarter valued at approximately $99,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.